Consistent with the observations in 4T1/67NR mouse models, breast tumors with signatures of low CD81+CD63+EVs had a significantly higher frequency of M2 macrophages (known to differentiate from M-MDSCs [52]) compared with tumors with signatures of high CD81+CD63+EVs. This evidence concerns the gene CD63 and breast neoplasm.